Deloitte and Vineti have entered into a teaming agreement for the collaborative development of end-to-end solutions to support personalised medicine.
Research collaboration
Through combining Vineti’s cell and gene therapy platform with Deloitte’s ConvergeHEALTH Patient Connect platform, the companies are aiming to offer a holistic one-stop solution to support life sciences innovators and healthcare professionals with the information systems to deliver on the promise of personalised medicine.
“The advancement of truly personalised therapies reinforces not just the belief but the practice that the patient is at the centre of therapeutic production, delivery and support,” said Amy DuRoss, CEO and co-founder of Vineti. “We are honoured to be teaming so closely with Deloitte and looking for opportunities to work with clients where we can integrate our offerings with their ConvergeHEALTH Patient Connect platform. This relationship will lead to holistic end-to-end services that connect automated supply chain workflows with a new level of support to the broader ecosystem and to patients.”
“Together, Vineti and ConvergeHEALTH Patient Connect’s care pathway support will bring an increasingly interdependent stakeholder group together in support of the patient in real time,” added DuRoss. “This can create an opportunity not just for better service and support, but also for better overall patient access, safety and outcomes.”
“The shift to value based, personalised healthcare requires new platforms to support not just the patient, but the myriad stakeholders it takes to deliver these targeted breakthroughs to patients,” commented Brett Davis, ConvergeHEALTH general manager and principal, Deloitte Consulting LLP. “Realising the promise of personalised medicine for patients is truly a team sport and we are excited to work with Vineti to address some of the most complex supply chain, workflow and patient engagement challenges to support personalised therapies for our clients.”
Vineti is a cloud-based software platform that safely and efficiently moves patient-based personalised therapies into mainstream medicine at scale. It is currently serving patients in more than 65 leading medical centres and expanding worldwide.
ConvergeHEALTH Patient Connect currently supports more than 300,000 patients globally in over 17 countries.
“Our investment in the ConvergeHEALTH Patient Connect ecosystem will continue with this exciting opportunity to integrate the Vineti solution for our clients,” said Chris Zant, ConvergeHEALTH chief digital officer and principal, Deloitte Consulting LLP. “Personalised medicine is changing all aspects of the industry including the way patients, providers and life sciences innovators interact and we believe that a solution that contains both Vineti and PatientConnect will bring an unprecedented level of real-time support and fidelity to control supply chain and care pathway management.”